NCT01967667已完成不适用
Biological Evaluation of Dietary Supplement Liposomal Glutathione
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 11
- 试验地点
- 2
- 主要终点
- Glutathione levels
研究概览
简要总结
Low levels of antioxidant molecules such as glutathione have been found in people with a diagnosis of schizophrenia. However, oral glutathione is not well absorbed because the compound is mostly broken down in the gastrointestinal system. Liposomes are tiny droplets of oil particles that encapsulate and protect the glutathione. In this study we will evaluate a liposomal formulation of glutathione for tolerability and to examine if this formulation serves the function of increasing glutathione in the brain and body.
详细描述
Additional information about this dietary supplement:
- Glutathione is an antioxidant naturally produced in our body. Glutathione protects the brain and other organs from oxidative stress.
- Low glutathione is associated with high oxidative stress, which has been linked to aging and many illnesses. Schizophrenia is a mental illness that doctors still do not fully understand. Individuals with schizophrenia often have low levels of glutathione.
- Glutathione can be supplied through dietary supplement. However, if taken plainly, it easily breaks down in our gut.
- Scientists have now found a way to wrap glutathione in tiny drops of oil particles called liposomes. That way, the gut cannot break it down so it is absorbed into our body. Once inside the body, our cells can take in the liposomes and use the glutathione to reduce oxidative stress.
- Liposome-wrapped glutathione is not a drug or medicine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age range: 18-60
- •DSM diagnosis of schizophrenia spectrum disorder, including schizophrenia, schizoaffective disorder, and schizophreniform disorder
- •Ability to give written informed consent (Evaluation to Sign Consent score 10 or greater)
- •Clinically stable with no change in antipsychotic medications nor significant increase of daily dose for 2 weeks prior to enrollment
- •Low baseline blood glutathione level (GSH < 890 umol/l)
排除标准
- •History of major medical illness including, but not limited to, history of heart attack, stroke, TIA (transient ischemic attack)
- •History of organic brain disorders that may affect neurophysiological measurements, including seizure disorder, brain tumor, head injury with evidence of significant cognitive deterioration
- •DSM diagnosis of substance dependence within 6 months except nicotine and marijuana, or substance abuse in past month
- •Uncontrolled blood pressure (persistent systolic above 165 or diastolic above 100)
- •On medication containing cholesterol absorption inhibitor such as ezetimibe (Brand names Zetia, Ezetrol, Vytorin, and Inegy)
- •Women who have positive urine pregnancy tests
- •Women who plan to become pregnant, or are breastfeeding
- •Unable to undergo MRI scanning due to metallic devices or objects or claustrophobia
- •Already taking dietary antioxidant supplements such as n-acetylcysteine or fish oil on regular basis (more than twice a week) in the last 3 months
- •History of allergy to soy or soy products
- •Hyperlipidemia (baseline LDL > 1.5 x upper limit of normal)
- •Liver impairment (baseline AST or ALT > 2.0 x upper limit of normal)
结局指标
主要结局
Glutathione levels
时间窗: Baseline and 3 weeks
Change of glutathione levels from baseline to following 3 weeks of treatment.
次要结局
- oxidative stress biomarker(baseline and 3 weeks)
- inflammatory marker(baseline and 3 weeks)
研究者
MPRC
Professor
University of Maryland, Baltimore
研究点 (2)
Loading locations...
相似试验
已完成
不适用
The Impact of Oral Glutathione on Oxidative Damage and Glycated Hemoglobin (HbA1c) Levels in Type 2 Diabetes PatientsType 2 DiabetesNCT06313164S.LAB (SOLOWAYS)217
招募中
2 期
Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)Smith-Lemli-Opitz SyndromeCone-Rod DystrophyHearing LossNCT01773278University of Colorado, Denver100
已完成
不适用
Oral Liposomal Glutathione Supplementation in Healthy SubjectsHealthyNCT02278822Milton S. Hershey Medical Center12
Unknown
不适用
Study of Supplement's Antioxidant Properties That Contains Natural ExtractsHealthyNCT02837107Harokopio University62
撤回
不适用
Glutathione (GSH) Supplementation After HospitalizationMalnutritionNCT03166371Emory University